1-6 of 6
Andrius Žucenka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Andrius Zucenka, Ghayas C. Issa, Martha Arellano, Sajad Khazal, Nandita Khera, Wendy Stock, Branko Cuglievan, Yu Gu, Huy Van Nguyen, Angela R. Smith, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 4950.
https://doi.org/10.1182/blood-2023-189036
Published: 2023
Journal Articles

HMR Mutations Drive Poor Prognosis in Myelofibrosis Patients with Lower JAK2 V617F Allele Burden but Not in Those with Higher Allele Burden: Results of a Multicenter Study

Yu-Hung Wang, Carmelo Gurnari, Chao-Hung Wei, Hussein Awada, Chien-Chin Lin, Andrius Zucenka, Chi-Yuan Yao, Kristian Gurashi, Hsin-An Hou, Kiran Batta, Wen-Chien Chou, Jaroslaw P. Maciejewski, Daniel H Wiseman, Hwei-Fang Tien
Journal: Blood
Blood (2023) 142 (Supplement 1): 627.
https://doi.org/10.1182/blood-2023-179907
Published: 2023
Journal Articles

Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients

Andrius Zucenka, Birutė Davainienė, Vilmantė Vaitekėnaitė, Rūta Čepulytė, Linas Davainis, Guoda Daukėlaitė, Lukas Kevličius, Regina Pileckytė, Igoris Trociukas, Laimonas Griškevičius
Journal: Blood
Blood (2023) 142 (Supplement 1): 6474.
https://doi.org/10.1182/blood-2023-178611
Published: 2023
Journal Articles

Venetoclax-Based Therapies for Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 in Clinical Practice Setting

Andrius Žucenka, Lukas Kevličius, Linas Davainis, Birutė Davainienė, Kazimieras Maneikis, Regina Pileckytė, Dominika Vasilevska, Igoris Trociukas, Vilmantė Vaitekėnaitė, Laimonas Griškevičius
Journal: Blood
Blood (2022) 140 (Supplement 1): 3358–3359.
https://doi.org/10.1182/blood-2022-165459
Published: 2022
Journal Articles

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

Ghayas C. Issa, Branko Cuglievan, Eytan Stein, Martha L. Arellano, Andrius Žucenka, Nandita Khera, Richard M. Stone, Michael J. Thirman, John F. DiPersio, Nicole Karras, Yu Gu, Rebecca G. Bagley, Galit Rosen, David Tamang, Kimberly Dishman, Sushama Scalera, Michael L. Meyers, Kate Madigan, Nicole McNeer, Ibrahim Aldoss
Journal: Blood
Blood (2022) 140 (Supplement 1): 914–916.
https://doi.org/10.1182/blood-2022-164600
Published: 2022
Journal Articles

Venetoclax, Actinomycin D and Low Dose Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia in Clinical Practice Setting

Andrius Zucenka, Vilmantė Vaitekėnaitė, Kazimieras Maneikis, Regina Pileckytė, Igoris Trociukas, Valdas Pečeliūnas, Laimonas Griškevičius
Journal: Blood
Blood (2021) 138 (Supplement 1): 3422.
https://doi.org/10.1182/blood-2021-144434
Published: 2021